Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $208M (up 38.6% year over year) with net income of −$2M.
Q1 2026 key financials · XBRL
- Revenue
- $208M
- +38.6% YoY
- Net income
- −$2M
- +80.6% YoY
- Operating margin
- -4.0%
- EPS (diluted)
- −$0.04
- +81.0% YoY
Source: XBRL data from the SUPERNUS PHARMACEUTICALS, INC. (SUPN) Q1 2026 10-Q on SEC EDGAR. USD.
SUPERNUS PHARMACEUTICALS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $207.7M, up 39% YoY from $149.8M, driven by ZURZUVAE and licensing revenue
- Net loss $2.3M vs $11.8M YoY; effective tax rate 61.5% vs (102.8)%
- Best product Qelbree: $77.8M, up 20%; worst APOKYN: $7.7M, down 48%
- Cash, securities and restricted cash $385.7M, up 24%; operating cash flow $66.5M vs $30.6M
- ONAPGO supply constraints eased; second-supplier FDA submission planned for third quarter 2026
Risk Factors
- No material changes to risk factors since the December 31, 2025 Form 10-K
- Investment risk: adverse events could materially harm business, financial condition, or results
- Market risk: adverse developments could reduce common-stock market price
- Investor risk: shareholders could lose part or all of their investment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SUPERNUS PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.